Citeline Podcasts

글로벌 제약업계는 암 연구의 미래를 어떻게 보고 있을까? Scrip의 ASCO 현장 취재 기사를 요약한 내용입니다.

https://scrip.citeline.com/SC150378/ASCO-Roundup-Looking-For-The-Future-Of-Cancer-Research

Playlist: https://soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini

Audio roundup of selected biopharma industry content from Scrip over the business week ended 7 June 2024. In this episode: BIO Notebook; ASCO roundup; data on Carvykti in community at ASCO; strong new results for tirzepatide in MASH; and orphan slowdown signals new path ahead.

https://scrip.citeline.com/SC150401/Quick-Listen-Scrips-Five-MustKnow-Things

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Generics Bulletin's editorial team discusses the latest strategic developments for major industry players Teva, Sandoz and Sawai, as well as explaining the recent debate over US patent listings in the FDA's Orange Book.

Guest speaker Guangzuo Luo, chief scientific officer of Bioncetech, joins China-based editors Brian Yang and Dexter Yan in this episode, which looks at Chinese biotechs going global, and the opportunities and challenges in the latest industry latest trends.

https://scrip.citeline.com/SC150370/China-Biotech-Podcast-Going-Global-Trends-Rare-Disease-Drug-Development

Playlist: https://soundcloud.com/citelinesounds/sets/chinese-language-biopharma?si=80b1209c44874afa9c44bf7d30538320&utm_source=clipboard&utm_medium=text&utm_campaign=social_sharing

In an interview with Scrip, JB CEO Nikhil Chopra addresses rumours of a sale of a stake in the Indian pharma/CDMO company by private equity fund KKR, recent acquisitions, including from Novartis, as well as JB's ambitions to ramp up the cardiology segment and its CDMO business, which already has major clients including J&J.

https://scrip.citeline.com/SC150350/Amid-Talk-Of-KKR-Stake-Sale-JB-CEO-Stresses-Business-As-Usual

Audio roundup of selected biopharma industry content from Scrip over the business week ended 31 May 2024. In this episode: ASCO preview; Asahi’s US acquisition; Novartis aims for renal disease dominance; paying for gene therapies; and US BIOSECURE Act diluted.

https://scrip.citeline.com/SC150361/Quick-Listen-Scrips-Five-MustKnow-Things

Playlist: https://soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

An interview with Genmab’s Jan van de Winkel to mark 25 years of the company, and 20 years of the Scrip Awards. A brief history of the antibody-focused biotech company so far, and its plans for future expansion.

In this episode we unpack the Corporate Sustainability Reporting Directive (CSRD) with the help of ESG expert Jasper Crone, drilling down into exactly what consumer healthcare companies need to know about this enormously complex and significant piece of EU legislation.

3:30 Introduction to the CSRD

7:45 What companies are affected by the CSRD

15:00 Specific implications for consumer health companies

21:00 Getting materiality right

25:00 CSRD to do list

32:00 Who’s afraid of targets?

37:00 Who’s responsible for CSRD in companies?

39:00 CSRD and the EU Green Deal

45:00 How will CSRD shape the way companies operate?

Advancing Investigational New Drugs (INDs) can be a complex process, especially for smaller companies. Listen to your free podcast now as Marcus Delatte, PhD, Vice President at Allucent and Harshini Neelakantan, Executive Director at Ridgeline Therapeutics discuss best practices and considerations for leveraging your pre-IND meeting and submitting a successful IND application.

Listen now for insights into:

• Current trends and challenges related to IND submissions

• The purpose and benefits of pre-IND meetings with regulatory bodies

• Indicators that should prompt companies to request a pre-IND meeting

• The role of consultants in supporting sponsors in pre-IND meetings

• Getting the most from your pre-IND meeting and tips for IND application success

• How IND submissions will evolve in the future

Astellas Pharma’s chief commercial officer, Claus Zieler, discusses the biopharma industry’s responsibility to drive change in health care.